International sepsis trial (INTERSEPT): Role and impact of a clinical evaluation committee

被引:44
作者
Sprung, CL
Finch, RG
Thijs, LG
Glauser, MP
机构
[1] UNIV NOTTINGHAM, NOTTINGHAM NG7 2RD, ENGLAND
[2] CITY HOSP NOTTINGHAM, NOTTINGHAM, ENGLAND
[3] VRIJE UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS
[4] CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND
关键词
Clinical Evaluation Committee; clinical trials; sepsis; septic shock; tumor necrosis factor; antimicrobial therapy; medical surgical management; do-not-resuscitate orders; critical illness; pharmacology;
D O I
10.1097/00003246-199609000-00003
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Several large clinical trials have recently evaluated a variety of potential therapeutic interventions for sepsis and have yielded negative results based on analyses of intention to treat cohorts, The present study was undertaken to evaluate the importance of a Clinical Evaluation Committee, Design: Prospective, double-blind evaluation of a prospective, controlled, double-blind, randomized, multinational trial, Setting: Forty medical centers, Patients: Five hundred fifty-three infused patients with severe sepsis and septic shock, Methods: As part of an international trial (INTERSEPT) of antitumor necrosis factor therapy, a Scientific Extramural Review Commitee prospectively defined and excluded patients with con founding events that objectively interfered with the potential of any intervention for sepsis to exercise its therapeutic effect, These confounding events included inappropriate antimicrobial therapy, inadequate medical-surgical management, underlying disorders, and forgoing life-sustaining therapies before management had failed, Patients who met all inclusion and exclusion criteria and who had no confounding events were defined as the Scientific Extramural Review Committee group, Measurements and Main Results: Five hundred fifty-three patients were enrolled in INTERSEPT, Seventy-seven patients did not meet inclusion and exclusion criteria, Sixty patients had confounding events, including inappropriate antimicrobial therapy (n = 28), inadequate medical-surgical management (n = 16), underlying disorders (n = 17), and forgoing life sustaining therapies (n = 7), Four hundred sixteen patients were in the Scientific Extramural Review Committee group and their mortality rates were different from the mortality rates of the intent to treat cohort, In the intent-to-treat analysis among shock patients, low dose anti-tumor necrosis factor reduced 28 day mortality by 14.5% (p = .34), whereas in the Scientific Extramural Review Committee group, the study drug reduced mortality by 26.5% (p = .16), More patients in the high dose anti-tumor necrosis factor treatment arm (31/176) were in the invalid Scientific Extramural Review Committee group than in the other two arms (16/157 and 13/143, respectively, p < .05), Conclusions: In large trials of sepsis, in addition to analyzing the intent to treat cohort, patients in compliance with the protocol and with no confounding events should also be analyzed, These results should assist in determining whether treatment groups are comparable and provide a greater likelihood of demonstrating the potential efficacy of a new therapy for sepsis, A Clinical Evaluation Committee is important to properly assess a clinical sepsis trial.
引用
收藏
页码:1441 / 1447
页数:7
相关论文
共 16 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]   A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK [J].
BONE, RC ;
FISHER, CJ ;
CLEMMER, TP ;
SLOTMAN, GJ ;
METZ, CA ;
BALK, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) :653-658
[3]   INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].
Cohen, J ;
Carlet, J .
CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440
[4]   PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL-TRIAL [J].
DHAINAUT, JFA ;
TENAILLON, A ;
LETULZO, Y ;
SCHLEMMER, B ;
SOLET, JP ;
WOLFF, M ;
HOLZAPFEL, L ;
ZENI, F ;
DREYFUSS, D ;
MIRA, JP ;
DEVATHAIRE, F ;
GUINOT, P .
CRITICAL CARE MEDICINE, 1994, 22 (11) :1720-1728
[5]   WHY HAVE NEW EFFECTIVE THERAPIES FOR SEPSIS NOT BEEN DEVELOPED [J].
EIDELMAN, LA ;
SPRUNG, CL .
CRITICAL CARE MEDICINE, 1994, 22 (08) :1330-1334
[6]   RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISHER, CJ ;
DHAINAUT, JFA ;
OPAL, SM ;
PRIBBLE, JP ;
BALK, RA ;
SLOTMAN, GJ ;
IBERTI, TJ ;
RACKOW, EC ;
SHAPIRO, MJ ;
GREENMAN, RL ;
REINES, HD ;
SHELLY, MP ;
THOMPSON, BW ;
LABRECQUE, JF ;
CATALANO, MA ;
KNAUS, WA ;
SADOFF, JC ;
ASTIZ, M ;
CARPATI, C ;
BONE, RC ;
FREIDMAN, B ;
MURE, AJ ;
BRATHWAITE, C ;
SHAPIRO, E ;
MELHORN, L ;
TAYLOR, R ;
KEEGAN, M ;
OBRIEN, J ;
SCHEIN, R ;
PENA, M ;
WASSERLOUF, M ;
OROPELLO, J ;
BENJAMIN, E ;
DELGUIDICE, R ;
EMMANUEL, G ;
LIE, T ;
ANDERSON, L ;
MARSHALL, J ;
DEMAJO, W ;
ROTSTEIN, O ;
FOSTER, D ;
ABRAHAM, E ;
MIDDLETON, H ;
PERRY, C ;
LEVY, H ;
FRY, DE ;
SIMPSON, SQ ;
CROWELL, RE ;
NEIDHART, M ;
STEVENS, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1836-1843
[7]   A CONTROLLED CLINICAL-TRIAL OF E5 MURINE MONOCLONAL IGM ANTIBODY TO ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS [J].
GREENMAN, RL ;
SCHEIN, RMH ;
MARTIN, MA ;
WENZEL, RP ;
MACINTYRE, NR ;
EMMANUEL, G ;
CHMEL, H ;
KOHLER, RB ;
MCCARTHY, M ;
PLOUFFE, J ;
RUSSELL, JA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (08) :1097-1102
[8]   OF MICE BUT NOT MEN - PROBLEMS OF THE RANDOMIZED CLINICAL-TRIAL [J].
HELLMAN, S ;
HELLMAN, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (22) :1585-1589
[9]   Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis [J].
Knaus, WA ;
Harrell, FE ;
LaBrecque, JF ;
Wagner, DP ;
Pribble, JP ;
Draper, EA ;
Fisher, CJ ;
Soll, L ;
Astiz, M ;
Rackow, EC ;
Carpati, C ;
Balk, RA ;
Friedman, B ;
Mure, AJ ;
Shapiro, E ;
Melhom, L ;
Shapiro, MJ ;
Taylor, R ;
Keegan, M ;
OBrien, J ;
Greenman, RL ;
Schein, R ;
Pena, M ;
Wasserlouf, M ;
Iberti, TJ ;
Oropello, J ;
Benjamin, E ;
DelGuidice, R ;
Emmanuel, G ;
Lie, T ;
Anderson, L ;
Marshall, J ;
DeMajo, W ;
Rotstein, O ;
Foster, D ;
Abraham, E ;
Middleton, H ;
Perry, C ;
Levy, H ;
Fry, DE ;
Simpson, SQ ;
Crowell, RE ;
Neidhart, M ;
Stevens, D ;
Coffman, T ;
Narasimhan, N ;
Merrick, DK ;
Berquist, W ;
Matzel, K ;
Huebler, M .
CRITICAL CARE MEDICINE, 1996, 24 (01) :46-56
[10]   TREATMENT OF SEPTIC SHOCK WITH HUMAN MONOCLONAL-ANTIBODY HA-1A - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
MCCLOSKEY, RV ;
STRAUBE, RC ;
SANDERS, C ;
SMITH, SM ;
SMITH, CR .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (01) :1-5